Axial spondyloarthritis manifests as a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. Although chronic back pain and spinal stiffness ... leads to irreversible ...

Axial spondyloarthritis is a chronic rheumatological disease that primarily affects the sacroiliac joints and the spine, but often also involves the peripheral skeleton and other organs. The disease ...

Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine and joints that connect the lower spine to the pelvis (known as the sacroiliac joints).

The primary symptoms of axial spondyloarthritis (axSpA), a chronic inflammatory disease, include back pain, fatigue, joint pain, heel pain, sleep problems, and abdominal pain. Symptoms vary from ...

The 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria, developed to identify patients with early or atypical disease which could not be classified by the 1984 ...

Psoriatic arthritis (PsA) is a seronegative inflammatory musculoskeletal disease that affects the peripheral joints, axial joints (spine) and entheses of subjects with psoriasis. PsA may lead to ...

Univariable and multivariable analyses were performed using the χ 2 test, independent Student's t-test, Mann-Whitney U test, logistic regression, linear regression, Poisson regression for non-normally ...

Middle age is when you get to know your joints. I have spent the last few years learning that my many youthful party tricks—popping shoulders out of their sockets on a whim, bending elbows ...

It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, pain and stiffness develop as inflammation spreads from the skin to the ...

A type of positional embedding that is very effective when working with attention networks on multi-dimensional data, or for language models in general.

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...